Prognostic implications of securin expression and sub-cellular localization in human breast cancer.

Purpose: Securin belongs to a class of cell cycle regulators that prevent metaphase-to-anaphase transition until sister chromatid separation is complete. Evidence is accumulating that securin has a prognostic impact on a variety of malignancies but, thus far, the role and regulation of securin expression and its sub-cellular localization have not been systematically addressed in breast cancer.

Methods: In total 470 breast cancer specimens with follow-up data for up to 22 years were included.

[Superior semicircular canal dehiscence as a cause of hearing loss].

Superior semicircular canal dehiscence can be the cause of hearing loss and vertigo. Typical findings are conductive hearing loss and hyperacusis to bone-conducted sounds. Also acute pressure- and sound-evoked vestibular symptoms may occur.

Altered expression of p120catenin predicts poor outcome in invasive breast cancer.

Purpose: The study focuses on p120catenin, a regulator of cell adhesion, which has previously been described in many malignancies and suggested with a role in invasion and metastatic behaviour. In this study, we investigate the role of altered immunoexpression of p120catenin isoforms in the prognosis of invasive breast cancer (n = 351).

Methods: We used cDNA microarrays to screen differences in gene expression in invasive breast cancer in general, and between local and metastasized disease particularly.

Securin promotes the identification of favourable outcome in invasive breast cancer.

Background: Securin is a recently recognised oncogene with multiple known functions in initiation, progression and cell cycle regulation in several malignant diseases, including breast carcinoma.

Methods: In this paper, the prognostic value of securin is evaluated by immunohistochemistry in 310 patients diagnosed with invasive breast cancer during a mammographic screening programme in Central Finland. All patients were directed to modern surgical and oncological treatments and were followed up for a maximum of 20 years.